Seller record · Telehealth service

Healthon

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: The site names no filling pharmacy. The product pages, the about page, the questions page and the terms stop at U.S.-licensed compounding pharmacies and a Healthon-affiliated pharmacy. 1 more criterion also fails; see the table below.

At a glance

HealthonTelehealth service

6/8criteria passed

Price: Semaglutide $189 a month, tirzepatide $295 a month
Sells: compounded semaglutide, compounded tirzepatide, and 6 more
FDA letters: 1 on file

Visit Healthon See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and tirzepatide beside NAD+ injections and nasal spray and sermorelin injections and tablets. An FDA warning letter from September 2025 names the company over its claims about compounded semaglutide and tirzepatide.

Operating entity Healthon Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Healthon's website; Healthon's terms condition page; Healthon's NAD+ product page; Healthon's sermorelin injection product page
S2	Prescription gating	PASS	Healthon's intro page on its forms storefront; Healthon's goals page on its forms storefront
S3	Pharmacy identification	FAIL	Healthon's about us page; Healthon's terms conditions; Healthon's FAQ
S4	Compounding disclosure	PASS	Healthon's compounded semaglutide product page; Healthon's weight loss program page
S5	Analytical documentation	FAIL	Healthon's about us page; Healthon's tirzepatide 1 product page
S6	Business address	PASS	Healthon's contact page; Healthon's terms condition page; Healthon's privacy policy 1 page
S7	Price disclosure	PASS	Healthon's weight loss program page; Healthon's compounded semaglutide product page; Healthon's NAD+ product page; Healthon's longevity program page
S8	Enforcement status	PASS	fda.gov; letter 719809

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed medical provider reviews each online health assessment, and the terms name Healthon Medical Group Inc. as the medical group. The NAD+ and sermorelin pages also say no prescription is needed, beside the footer line that medications are available only if prescribed after a consultation.Source: Healthon's website; Healthon's terms condition page; Healthon's NAD+ product page; Healthon's sermorelin injection product page.

S2PASSEvery product button opens an eligibility intake that asks about goals and health before any plan is chosen, and no product page carries a cart.Source: Healthon's intro page on its forms storefront; Healthon's goals page on its forms storefront.

S3FAILThe site names no filling pharmacy. The product pages, the about page, the questions page and the terms stop at U.S.-licensed compounding pharmacies and a Healthon-affiliated pharmacy.Source: Healthon's about us page; Healthon's terms conditions; Healthon's FAQ.

S4PASSEach product page states that the medication is compounded and has not been evaluated or approved by the FDA, and the home page, program pages and footer repeat that compounded drugs are not FDA-approved.Source: Healthon's compounded semaglutide product page; Healthon's weight loss program page.

S5FAILNo certificate of analysis or lot document is published. The product and about pages show potency, sterility, pH and endotoxin tests marked as passed, with no report behind them.Source: Healthon's about us page; Healthon's tirzepatide 1 product page.

S6PASSHealthon Inc. at 100 Spectrum Center Dr #900, Irvine, CA 92618, printed on the contact page, in the terms and in the privacy policy.Source: Healthon's contact page; Healthon's terms condition page; Healthon's privacy policy 1 page.

S7PASSCompounded semaglutide at $189 a month on a monthly plan or $549 a quarter, and compounded tirzepatide at $295 a month or $837 a quarter, on the weight loss program page. The semaglutide product page ties its $189 starting figure to a 12-month plan paid upfront instead. The NAD+ injection starts at $195 a month and sermorelin injection at $155 a month on a 6-month plan.Source: Healthon's weight loss program page; Healthon's compounded semaglutide product page; Healthon's NAD+ product page; Healthon's longevity program page.

S8PASSFDA warning letter 719809, September 2025, names Healthon Inc. dba Healthon at 100 Spectrum Center Dr #900, Irvine, California, alleging that claims about its compounded semaglutide and tirzepatide, including the same active ingredient as Wegovy and Ozempic, are false or misleading. No FDA action has halted the business, and the seller continues to operate.Source: fda.gov; letter 719809.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+ injection and nasal spray, sermorelin injection and ODT, metformin, PT-141, sildenafil and tadalafil, hair loss medications.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells PT-141

Enforcement documents on file: 1 warning letter

FDA warning letter 719809, issued September 2025, to Healthon Inc. dba HealthonThe site claimed the same active ingredient as Wegovy, Ozempic, Mounjaro and Zepbound, clinically proven weight loss, and that the active ingredient in its formula is FDA-approved, claims the letter says present the compounded semaglutide and tirzepatide as FDA-approved products when they are not.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Unpaid link. Healthon does not pay the site, and nothing is earned when it is used. Funding.

Visit Healthon

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.